UBS AM
CRMD icon

UBS AM’s CorMedix CRMD Stock Holding History

UBS AM’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$893K Sell
113,740
-58,142
-34% -$459K ﹤0.01% 2378
2026
Q1 		$1.17M Buy
171,882
+61,596
+56% +$455K ﹤0.01% 2286
2025
Q4 		$1.28M Sell
110,286
-6,538
-6% -$72.3K ﹤0.01% 2055
2025
Q3 		$1.36M Sell
116,824
-73,018
-38% -$883K ﹤0.01% 1897
2025
Q2 		$2.34M Buy
189,842
+84,166
+80% +$929K ﹤0.01% 2079
2025
Q1 		$651K Buy
+105,676
New +$1.09M ﹤0.01% 2440

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS AM's CRMD Position: Q2 2026 in Review

UBS AM reduced its CorMedix (CRMD) stake by 34% in Q2 2026, selling an estimated $459K and leaving 113,740 shares worth $893K. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

UBS AM first reported a position in CRMD in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.34M in Q2 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • UBS AM held 113,740 shares of CorMedix worth $893K as of Q2 2026.
  • UBS AM sold 58,142 CorMedix shares in Q2 2026, an estimated $459K.
  • CorMedix made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2378 holding.
  • UBS AM first reported a position in CorMedix in Q1 2025 and has held it in 6 quarters since.
  • UBS AM's CorMedix position peaked at $2.34M in Q2 2025.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.